Investors of Capricor Therapeutics Need to Know About Ongoing Securities Fraud Case

Overview of the Lawsuit Against Capricor Therapeutics, Inc.

The recent class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) has garnered significant attention among investors and stakeholders alike. Initiated by the national shareholder rights firm Schall, Brown & Schwartz LLP (commonly referred to as SBS Law), this lawsuit alleges severe violations of U.S. securities laws. The legal case concerns the misrepresentation of critical information related to clinical trials and the submission of the Biologics License Application (BLA) involving Deramiocel, a product that has been under scrutiny.

Details of the Allegations

According to the complaint filed, shareholders who acquired Capricor's stock during the specified class period from December 17, 2025, to July 26, 2026, could be entitled to compensation. The firm contends that Capricor made various false and misleading statements regarding its statistical analysis plan aimed at evaluating clinical data. Notably, the alleged misconduct includes changes made to the analysis plan without prior approval from the FDA, which raises questions about the integrity of the company's submissions and communications to its investors and the public.

The complaint outlines that the alteration of this plan posed a significant risk, potentially harming the company’s credibility, especially concerning the anticipated approval of the BLA. It suggests that Capricor's public statements concerning the viability and effectiveness of Deramiocel were fundamentally untrue, which ultimately led to substantial financial losses for investors once the true nature of the situation was disclosed.

Call to Action for Investors

Shareholders who have experienced financial losses linked to their investments in Capricor are encouraged to participate in the lawsuit and explore options to be appointed as lead plaintiffs. While the class has not yet been certified, individuals who choose not to take action remain absent class members, which could affect their ability to seek recovery.

SBS Law has stated that interested investors can reach out directly for consultations about their options and potential recovery without any obligations. They emphasize that you don’t need to be appointed lead plaintiff to join the case and make a claim.

Important Dates and Deadlines

Investors should take note of the approaching deadline of September 28, 2026, for filing their claims as part of the class action. As the legal proceedings continue, it’s crucial for affected shareholders to seek professional legal guidance to understand their rights thoroughly.

Why Choose SBS Law?

Schall, Brown & Schwartz LLP boasts a dedicated team specializing in shareholder rights litigation and securities class actions, offering comprehensive representation for investors worldwide. Their partners, including Brian Schall, Andrew Brown, and David Schwartz, are recognized for their commitment to advocating aggressively for the rights of their clients. The firm aims to empower investors by providing knowledge of their legal rights and engaging them in the fight for justice.

Conclusion

As the case progresses, it’s vital for investors associated with Capricor Therapeutics, Inc. to stay informed and engaged. The allegations of securities fraud against Capricor could have significant implications, making it essential to assess one’s position in the matter promptly. For more detailed information, shareholders are encouraged to visit the SBS Law website for up-to-date resources and advice on how to proceed with their claims.